menu
    • menu

    Find Chlorambucil manufacturers, exporters & distributors on PharmaCompass

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass

    Synopsis

    Product SearchProduct Search

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    5

    API Suppliers

    API Suppliers

    1

    USDMF

    US DMFs Filed

    1

    CEP/COS

    CEP/COS Certifications

    0

    JDMF

    JDMFs Filed

    1

    EU WC

    EU WC

    0

    KDMF

    KDMF

    4

    NDC API

    NDC API

    0

    VMF

    NDC API

    5

    Listed Suppliers

    Other Suppliers

    API REF. PRICE (USD/KG)

    $
    $ 24,874

    MARKET PLACE

    1

    API

    3

    FDF

    1INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    12

    FDF Dossiers

    FDF Dossiers

    1

    FDA Orange Book

    FDA (Orange Book)

    5

    Europe

    Europe

    1

    Canada

    Canada

    1

    Australia

    Australia

    1

    South Africa

    South Africa

    3

    Listed Dossiers

    Listed Dossiers

    1DRUGS IN DEVELOPMENT

    FDF Dossiers

    DRUG PRODUCT COMPOSITIONS

    REF. STANDARDS OR IMPURITIES

    1

    EDQM

    1

    USP

    0

    JP

    2

    Others

    PATENTS & EXCLUSIVITIES

    0

    US Patents

    0

    US Exclusivities

    0

    Health Canada Patents

    DIGITAL CONTENT

    5

    Data Compilation #PharmaFlow

    0

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    18

    News #PharmaBuzz

    GLOBAL SALES INFORMATION

    US Medicaid

    5,022,744

    Annual Reports

    NA

    Finished Drug Prices

    Listed Dossiers

    127 RELATED EXCIPIENT COMPANIES

    211EXCIPIENTS BY APPLICATIONS

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: 305-03-3, Ambochlorin, Leukeran, Chloroambucil, Chloraminophen, Chlorbutin
    Molecular Formula
    C14H19Cl2NO2
    Molecular Weight
    304.2  g/mol
    InChI Key
    JCKYGMPEJWAADB-UHFFFAOYSA-N
    FDA UNII
    18D0SL7309
    Chlorambucil
    A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed)
    Chlorambucil is an Alkylating Drug. The mechanism of action of chlorambucil is as an Alkylating Activity.
    1 2D Structure

    Chlorambucil

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    4-[4-[bis(2-chloroethyl)amino]phenyl]butanoic acid
    2.1.2 InChI
    InChI=1S/C14H19Cl2NO2/c15-8-10-17(11-9-16)13-6-4-12(5-7-13)2-1-3-14(18)19/h4-7H,1-3,8-11H2,(H,18,19)
    2.1.3 InChI Key
    JCKYGMPEJWAADB-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    C1=CC(=CC=C1CCCC(=O)O)N(CCCl)CCCl
    2.2 Other Identifiers
    2.2.1 UNII
    18D0SL7309
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. 4-(bis(2-chloroethyl)amino)benzenebutanoic Acid

    2. Amboclorin

    3. Cb 1348

    4. Cb-1348

    5. Cb1348

    6. Chloraminophene

    7. Chlorbutin

    8. Leukeran

    9. Lympholysin

    10. N,n-di-(2-chloroethyl)-p-aminophenylbutyric Acid

    11. Nsc 3088

    12. Nsc-3088

    13. Nsc3088

    2.3.2 Depositor-Supplied Synonyms

    1. 305-03-3

    2. Ambochlorin

    3. Leukeran

    4. Chloroambucil

    5. Chloraminophen

    6. Chlorbutin

    7. Chloraminophene

    8. Chlorobutine

    9. Amboclorin

    10. Ecloril

    11. Chlorbutine

    12. Chlorobutin

    13. Lympholysin

    14. Chlocambucil

    15. Linfolizin

    16. Linfolysin

    17. Elcoril

    18. Phenylbutyric Acid Nitrogen Mustard

    19. Leukersan

    20. Leukoran

    21. 4-{4-[bis(2-chloroethyl)amino]phenyl}butanoic Acid

    22. Chlorambucilum

    23. Nsc-3088

    24. Cb L348

    25. Cb 1348

    26. Phenylbuttersaeure-lost

    27. Benzenebutanoic Acid, 4-[bis(2-chloroethyl)amino]-

    28. Nsc 3088

    29. Rcra Waste Number U035

    30. Cb-1348

    31. Nci-c03485

    32. 4-[p-[bis(2-chloroethyl)amino]phenyl]butyric Acid

    33. 4-(4-(bis(2-chloroethyl)amino)phenyl)butanoic Acid

    34. 4-[4-[bis(2-chloroethyl)amino]phenyl]butanoic Acid

    35. N,n-di-2-chloroethyl-gamma-p-aminophenylbutyric Acid

    36. 4-(bis(2-chloroethyl)amino)benzenebutanoic Acid

    37. P-(n,n-di-2-chloroethyl)aminophenyl Butyric Acid

    38. 4-(p-bis(beta-chloroethyl)aminophenyl)butyric Acid

    39. Benzenebutanoic Acid, 4-(bis(2-chloroethyl)amino)-

    40. Chebi:28830

    41. Nsc3088

    42. 4-[bis(2-chloroethyl)amino]benzenebutyric Acid

    43. 4-[bis(2-chloroethyl)amino]benzenebutanoic Acid

    44. Chembl515

    45. 4-(p-(bis(2-chloroethyl)amino)phenyl)butyric Acid

    46. Gamma-[p-di(2-chloroethyl)aminophenyl]butyric Acid

    47. Mls000028443

    48. Chloorambucol

    49. Chlorbutinum

    50. Elcorin

    51. 4-(bis(2-chloroethyl)amino)phenylbutyric Acid

    52. Nci-3088

    53. Gamma-(p-di(2-chloroethyl)aminophenyl)butyric Acid

    54. Butyric Acid, 4-(p-bis(2-chloroethyl)aminophenyl)-

    55. 18d0sl7309

    56. Kyselina 4-(n,n-bis-(2-chlorethyl)-p-aminofenyl)maselna

    57. Ncgc00015199-08

    58. Clorambucile

    59. Clorambucilo

    60. Cas-305-03-3

    61. Smr000058372

    62. Clorambucile [dcit]

    63. Dsstox_cid_263

    64. Leukeran Tablets

    65. 4-[bis(2-chloroethyl)amino]phenylbutyric Acid

    66. Dsstox_rid_75472

    67. Dsstox_gsid_20263

    68. 4-(4-[bis(2-chloroethyl)amino]phenyl)butyric Acid

    69. .gamma.-[p-di(2-chloroethyl)aminophenyl]butyric Acid

    70. Butyric Acid, 4-[p-[bis(2-chloroethyl)amino]phenyl]-

    71. Chlorambucilum [inn-latin]

    72. Clorambucilo [inn-spanish]

    73. P-n,n-di-(.beta.-chloroethyl)aminophenyl Butyric Acid

    74. N,n-di-2-chloroethyl-.gamma.-p-aminophenylbutyric Acid

    75. Ccris 126

    76. Phenylbuttersaeure-lost [german]

    77. Hsdb 3026

    78. Sr-01000000062

    79. Leukeran (tn)

    80. 4-[4-[bis(2-chloroethyl)amino]phenyl]butyric Acid

    81. Einecs 206-162-0

    82. .gamma.-(p-bis(2-chloroethyl)aminophenyl)butyric Acid

    83. .gamma.-[p-bis(2-chloroethyl)aminophenyl]butyric Acid

    84. 4-(p-bis(.beta.-chloroethyl)aminophenyl)butyric Acid

    85. 4-[p-bis(.beta.-chloroethyl)aminophenyl]butyric Acid

    86. Rcra Waste No. U035

    87. Butyric Acid, 4-(p-[bis(2-chloroethyl)amino]phenyl)-

    88. Brn 0999011

    89. Chlorambucilddv

    90. Chlorambucil [usp:inn:ban]

    91. Ai3-26083

    92. Unii-18d0sl7309

    93. P-(n,n-di-2-chlorethylaminophenyl)butyric Acid

    94. Para-(di(2-chloroethyl)aminophenyl)butyric Acid

    95. Chlorambucil,(s)

    96. Gamma-(p-bis(2-chloroethyl)aminophenyl)butyricacid

    97. Butanoic Acid, 4-(bis(2-chloroethyl)amino) Benzene

    98. Gamma-(p-bis(2-chloroethyl)aminophenyl)butyric Acid

    99. Phenyl)butanoic Acid

    100. Mfcd00021783

    101. P-n,n-di-(beta-chloroethyl)aminophenyl Butyric Acid

    102. Butyric Acid, 4-(p-(bis(2-chloroethyl)amino)phenyl)

    103. Para-n,n-di(beta-chloroethyl)aminophenyl Butyric Acid

    104. N,n-di-2-chloroethyl-gamma-para-aminophenyl Butyric Acid

    105. Opera_id_51

    106. Spectrum_000118

    107. Kyselina 4-(n,n-bis-(2-chlorethyl)-p-aminofenyl)maselna [czech]

    108. Prestwick0_001079

    109. Prestwick1_001079

    110. Prestwick2_001079

    111. Prestwick3_001079

    112. Spectrum2_000065

    113. Spectrum3_000336

    114. Spectrum4_000273

    115. Spectrum5_000677

    116. Chlorambucil [mi]

    117. Lopac-c-0253

    118. Chlorambucil [inn]

    119. Chlorambucil [jan]

    120. Epitope Id:139977

    121. Chlorambucil [hsdb]

    122. Chlorambucil [iarc]

    123. Schembl4308

    124. Chlorambucil [vandf]

    125. Chlorambucil With Impurity G

    126. Lopac0_000227

    127. Wln: Qv3r Dn2g2g

    128. Bspbio_001098

    129. Bspbio_001971

    130. Chlorambucil [mart.]

    131. Kbiogr_000766

    132. Kbioss_000558

    133. 4-14-00-01715 (beilstein Handbook Reference)

    134. Mls001076130

    135. Chlorambucil [usp-rs]

    136. Chlorambucil [who-dd]

    137. Chlorambucil [who-ip]

    138. Divk1c_000688

    139. Spectrum1500171

    140. Chlorambucil (jan/usp/inn)

    141. Spbio_000249

    142. Spbio_002999

    143. Bpbio1_001208

    144. Gtpl7143

    145. Zinc1115

    146. Dtxsid7020263

    147. Hms502c10

    148. Kbio1_000688

    149. Kbio2_000558

    150. Kbio2_003126

    151. Kbio2_005694

    152. Kbio3_001191

    153. Ninds_000688

    154. Chlorambucil [orange Book]

    155. Chlorambucil For System Suitability

    156. Hms1571g20

    157. Hms1920m15

    158. Hms2090m19

    159. Hms2091a22

    160. Hms2098g20

    161. Hms2235a04

    162. Hms3259i10

    163. Hms3372o04

    164. Hms3652p08

    165. Pharmakon1600-01500171

    166. 4-(4-(bis(2-chloroethyl)amino)

    167. Chlorambucil [ep Monograph]

    168. Amy33445

    169. Bcp28394

    170. Chlorambucil [usp Monograph]

    171. Tox21_110096

    172. Tox21_201390

    173. Tox21_302996

    174. Bdbm50003677

    175. Ccg-39872

    176. Nsc756674

    177. S4288

    178. Chlorambucilum [who-ip Latin]

    179. Akos024319346

    180. Tox21_110096_1

    181. Chlorambucil, Purum, >=98.0% (t)

    182. Cs-3118

    183. Db00291

    184. Gs-6200

    185. Lp00227

    186. Nc00555

    187. Nsc-756674

    188. Sdccgsbi-0050215.p005

    189. Idi1_000688

    190. Ncgc00015199-01

    191. Ncgc00015199-02

    192. Ncgc00015199-03

    193. Ncgc00015199-04

    194. Ncgc00015199-05

    195. Ncgc00015199-06

    196. Ncgc00015199-07

    197. Ncgc00015199-09

    198. Ncgc00015199-10

    199. Ncgc00015199-11

    200. Ncgc00015199-12

    201. Ncgc00015199-13

    202. Ncgc00015199-14

    203. Ncgc00015199-15

    204. Ncgc00015199-16

    205. Ncgc00015199-17

    206. Ncgc00015199-19

    207. Ncgc00015199-20

    208. Ncgc00023250-00

    209. Ncgc00023250-03

    210. Ncgc00023250-04

    211. Ncgc00023250-05

    212. Ncgc00023250-06

    213. Ncgc00023250-07

    214. Ncgc00023250-08

    215. Ncgc00023250-09

    216. Ncgc00023250-10

    217. Ncgc00256464-01

    218. Ncgc00258941-01

    219. Bp-24028

    220. Hy-13593

    221. Nci60_002639

    222. Sbi-0050215.p004

    223. Db-047794

    224. Wr-139013

    225. Ab00051938

    226. Eu-0100227

    227. Ft-0617365

    228. Sw197258-4

    229. A14252

    230. A18607

    231. C 0253

    232. C06900

    233. D00266

    234. H10484

    235. Ab00051938-14

    236. Ab00051938-15

    237. Ab00051938_16

    238. 305c033

    239. Q415939

    240. 4-(4-(bis(2-chloroethyl)amino)phenyl)butanoicacid

    241. 4[p-bis(.beta.-chloroethyl)aminophenyl]butyric Acid

    242. Butanoic Acid, 4-(bis(2-chloroethyl)amino)benzene-

    243. Sr-01000000062-2

    244. Sr-01000000062-4

    245. Sr-01000000062-7

    246. W-106940

    247. .gamma.-(p-bis(2-chloroethyl)aminophenyl)butyricacid

    248. Brd-k29458283-001-04-2

    249. Brd-k29458283-001-05-9

    250. Brd-k29458283-001-17-4

    251. 4-(4-[bis(2-chloroethyl)amino]phenyl)butanoic Acid #

    252. Z1558572529

    253. 4-[4-(n,n-bis(2-chloroethyl)-amino]phenyl)butanoic Acid

    254. Chlorambucil, European Pharmacopoeia (ep) Reference Standard

    255. Chlorambucil, United States Pharmacopeia (usp) Reference Standard

    256. Chlorambucil For System Suitability, European Pharmacopoeia (ep) Reference Standard

    2.4 Create Date
    2005-03-25
    3 Chemical and Physical Properties
    Molecular Weight 304.2 g/mol
    Molecular Formula C14H19Cl2NO2
    XLogP31.7
    Hydrogen Bond Donor Count1
    Hydrogen Bond Acceptor Count3
    Rotatable Bond Count9
    Exact Mass303.0792842 g/mol
    Monoisotopic Mass303.0792842 g/mol
    Topological Polar Surface Area40.5 Ų
    Heavy Atom Count19
    Formal Charge0
    Complexity250
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Information
    1 of 2  
    Drug NameLeukeran
    PubMed HealthChlorambucil (By mouth)
    Drug ClassesAntineoplastic Agent
    Drug LabelLEUKERAN (chlorambucil) was first synthesized by Everett et al. It is a bifunctional alkylating agent of the nitrogen mustard type that has been found active against selected human neoplastic diseases. Chlorambucil is known chemically as 4-[b...
    Active IngredientChlorambucil
    Dosage FormTablet
    RouteOral
    Strength2mg
    Market StatusPrescription
    CompanyAspen Global

    2 of 2  
    Drug NameLeukeran
    PubMed HealthChlorambucil (By mouth)
    Drug ClassesAntineoplastic Agent
    Drug LabelLEUKERAN (chlorambucil) was first synthesized by Everett et al. It is a bifunctional alkylating agent of the nitrogen mustard type that has been found active against selected human neoplastic diseases. Chlorambucil is known chemically as 4-[b...
    Active IngredientChlorambucil
    Dosage FormTablet
    RouteOral
    Strength2mg
    Market StatusPrescription
    CompanyAspen Global

    4.2 Therapeutic Uses

    Antineoplastic Agents, Alkylating; Carcinogens

    National Library of Medicine's Medical Subject Headings online file (MeSH, 2009)

    Chlorambucil is indicated in the treatment of chronic lymphatic (lymphocytic) leukemia, malignant lymphomas including lymphosarcoma, giant follicular lymphoma, and Hodgkin's disease. It is not curative in any of these disorders but may produce clinically useful palliation. /Include in US product label/

    US Natl Inst Health; DailyMed. Current Medication Information for LEUKERAN (chlorambucil) tablet, film coated (November 2012). Available from, as of March 1, 2012: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6b2023e7-50dc-49c3-949d-1bc10ba256f0

    Chlorambucil is considered by many clinicians to be the drug of choice for the treatment of (Waldenstrom's) macroglobulinemia. /Not included in US product label/

    American Society of Health-System Pharmacists 2011; Drug Information 2011. Bethesda, MD. 2011, p. 981

    Chlorambucil has also been used effectively with prednisone in the treatment of children with minimal-change nephrotic syndrome (lipoid nephrosis, idiopathic nephrotic syndrome of childhood) who have frequent relapses, require corticosteroid therapy to maintain remissions, or whose disease is resistant to steroid therapy. In most of these children, chlorambucil and prednisone therapy has induced long-term remissions and decreased the frequency of relapses. Although this type of nephrotic syndrome only occasionally occurs in adults, it is treated similarly. /Not included in US product label/

    American Society of Health-System Pharmacists 2011; Drug Information 2011. Bethesda, MD. 2011, p. 981

    For more Therapeutic Uses (Complete) data for CHLORAMBUCIL (9 total), please visit the HSDB record page.

    4.3 Drug Warning

    /BOXED WARNING/ Chlorambucil can severely suppress bone marrow function. Chlorambucil is a carcinogen in humans. Chlorambucil is probably mutagenic and teratogenic in humans. Chlorambucil produces human infertility.

    US Natl Inst Health; DailyMed. Current Medication Information for LEUKERAN (chlorambucil) tablet, film coated (December 2011). Available from, as of March 1, 2012: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6b2023e7-50dc-49c3-949d-1bc10ba256f0

    Chlorambucil is contraindicated in patients with known hypersensitivity to the drug or in patients whose disease was resistant to prior therapy with the drug. The manufacturer states that there may be cross-sensitivity between chlorambucil and other alkylating agents manifested as rash. Chlorambucil should be discontinued promptly in patients who develop skin reactions.

    American Society of Health-System Pharmacists 2011; Drug Information 2011. Bethesda, MD. 2011, p. 982

    Adverse hematologic effects are the major and dose-limiting effects of chlorambucil. In usual doses, myelosuppression generally occurs gradually, is moderate in severity, and is usually reversible following discontinuance of the drug. Leukopenia, resulting from neutropenia and slowly progressive lymphopenia, occurs in many patients receiving chlorambucil. Thrombocytopenia and anemia may also occur.

    American Society of Health-System Pharmacists 2011; Drug Information 2011. Bethesda, MD. 2011, p. 981

    Chlorambucil appears to be relatively free of adverse GI effects unless single doses of 20 mg or more are administered. Adverse GI effects include nausea, vomiting, gastric discomfort or abdominal pain, anorexia, and diarrhea. Adverse GI effects are usually mild, last less than 24 hours, and disappear despite continued treatment; however, nausea and weakness have persisted up to 7 days in some patients following a single, high dose of the drug. If necessary, nausea and vomiting may usually be controlled with antiemetics. Oral ulceration has also been reported.

    American Society of Health-System Pharmacists 2011; Drug Information 2011. Bethesda, MD. 2011, p. 981

    For more Drug Warnings (Complete) data for CHLORAMBUCIL (25 total), please visit the HSDB record page.

    4.4 Drug Indication

    For treatment of chronic lymphatic (lymphocytic) leukemia, childhood minimal-change nephrotic syndrome, and malignant lymphomas including lymphosarcoma, giant follicular lymphoma, Hodgkin's disease, non-Hodgkin's lymphomas, and Waldenstrms Macroglobulinemia.

    5 Pharmacology and Biochemistry
    5.1 Pharmacology

    Chlorambucil is an antineoplastic in the class of alkylating agents that is used to treat various forms of cancer. Alkylating agents are so named because of their ability to add alkyl groups to many electronegative groups under conditions present in cells. They stop tumor growth by cross-linking guanine bases in DNA double-helix strands - directly attacking DNA. This makes the strands unable to uncoil and separate. As this is necessary in DNA replication, the cells can no longer divide. In addition, these drugs add methyl or other alkyl groups onto molecules where they do not belong which in turn inhibits their correct utilization by base pairing and causes a miscoding of DNA. Alkylating agents are cell cycle-nonspecific. Alkylating agents work by three different mechanisms all of which achieve the same end result - disruption of DNA function and cell death.

    5.2 MeSH Pharmacological Classification

    Antineoplastic Agents, Alkylating

    A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026) (See all compounds classified as Antineoplastic Agents, Alkylating.)

    5.3 FDA Pharmacological Classification
    5.3.1 Active Moiety
    CHLORAMBUCIL
    5.3.2 FDA UNII
    18D0SL7309
    5.3.3 Pharmacological Classes
    Alkylating Drug [EPC]; Alkylating Activity [MoA]
    5.4 ATC Code

    L01AA02

    S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355

    L - Antineoplastic and immunomodulating agents

    L01 - Antineoplastic agents

    L01A - Alkylating agents

    L01AA - Nitrogen mustard analogues

    L01AA02 - Chlorambucil

    5.5 Absorption, Distribution and Excretion

    Route of Elimination

    Chlorambucil is extensively metabolized in the liver primarily to phenylacetic acid mustard. The pharmacokinetic data suggests that oral chlorambucil undergoes rapid gastrointestinal absorption and plasma clearance and that it is almost completely metabolized, having extremely low urinary excretion.

    Chlorambucil is rapidly and completely absorbed from the GI tract. Following single oral doses of 0.6-1.2 mg/kg, peak plasma concentrations of chlorambucil are reached within 1 hour.

    American Society of Health-System Pharmacists 2011; Drug Information 2011. Bethesda, MD. 2011, p. 983

    In a limited number of patients given a single oral dose of chlorambucil 0.2 mg/kg, an average peak plasma chlorambucil concentration of 492 ng/mL (adjusted to a dose of 12 mg) was reached at about 0.83 hours, and a mean peak plasma concentration of phenylacetic acid mustard (the major metabolite of chlorambucil) of 306 ng/mL (adjusted to a chlorambucil dose of 12 mg) occurred at approximately 1.9 hours. The area under the plasma concentration-time curve (AUC) of phenylacetic acid mustard was about 1.36 times greater than the AUC of chlorambucil.

    American Society of Health-System Pharmacists 2011; Drug Information 2011. Bethesda, MD. 2011, p. 983

    In a study of 12 patients given single oral doses of 0.2 mg/kg of chlorambucil, the mean dose (12 mg) adjusted (+/-SD) plasma chlorambucil Cmax was 492 +/- 160 ng/mL, the AUC was 883 +/- 329 ng.hr/mL, t1/2 was 1.3 +/- 0.5 hours, and the tmax was 0.83 +/- 0.53 hours. For the major metabolite, phenylacetic acid mustard, the mean dose (12 mg) adjusted (+/- SD) plasma Cmax was 306 +/- 73 ng/mL, the AUC was 1204 +/- 285 ng.h/mL, the t1/2 was 1.8 +/- 0.4 hours, and the tmax was 1.9 +/- 0.7 hours.

    US Natl Inst Health; DailyMed. Current Medication Information for LEUKERAN (chlorambucil) tablet, film coated (November 2012). Available from, as of March 1, 2012: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6b2023e7-50dc-49c3-949d-1bc10ba256f0

    Chlorambucil and its metabolites are extensively bound to plasma and tissue proteins. In vitro, chlorambucil is 99% bound to plasma proteins, specifically albumin.

    US Natl Inst Health; DailyMed. Current Medication Information for LEUKERAN (chlorambucil) tablet, film coated (November 2012). Available from, as of March 1, 2012: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6b2023e7-50dc-49c3-949d-1bc10ba256f0

    For more Absorption, Distribution and Excretion (Complete) data for CHLORAMBUCIL (12 total), please visit the HSDB record page.

    5.6 Metabolism/Metabolites

    Chlorambucil undergoes rapid metabolism to phenylacetic acid mustard, the major metabolite, and the combined chlorambucil and phenylacetic acid mustard urinary excretion is extremely low - less than 1% in 24 hours.

    US Natl Inst Health; DailyMed. Current Medication Information for LEUKERAN (chlorambucil) tablet, film coated (November 2012). Available from, as of March 1, 2012: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6b2023e7-50dc-49c3-949d-1bc10ba256f0

    Chlorambucil and its major metabolite spontaneously degrade in vivo forming monohydroxy and dihydroxy derivatives.

    US Natl Inst Health; DailyMed. Current Medication Information for LEUKERAN (chlorambucil) tablet, film coated (November 2012). Available from, as of March 1, 2012: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6b2023e7-50dc-49c3-949d-1bc10ba256f0

    Chlorambucil is extensively metabolized in rodents by monochloroethylation and by beta oxidation, forming the phenylacetic acid derivative, which also has anticancer activity.

    IARC. Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Geneva: World Health Organization, International Agency for Research on Cancer, 1972-PRESENT. (Multivolume work). Available at: https://monographs.iarc.fr/ENG/Classification/index.php, p. V26 123 (1981)

    Ten metabolites of chlorambucil were isolated, most of which were phenylacetic acid & benzoic acid derivatives.

    PMID:868079 MITOMA C ET AL; XENOBIOTICA 7 (4): 205-20 (1977)

    5.7 Biological Half-Life

    1.5 hours

    In a study of 12 patients given single oral doses of 0.2 mg/kg of chlorambucil, ... t1/2 was 1.3 +/- 0.5 hours, and the tmax was 0.83 +/- 0.53 hours. For the major metabolite, phenylacetic acid mustard, ... the t1/2 was 1.8 +/- 0.4 hours, and the tmax was 1.9 +/- 0.7 hours.

    US Natl Inst Health; DailyMed. Current Medication Information for LEUKERAN (chlorambucil) tablet, film coated (November 2012). Available from, as of March 1, 2012: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6b2023e7-50dc-49c3-949d-1bc10ba256f0

    5.8 Mechanism of Action

    Alkylating agents work by three different mechanisms: 1) attachment of alkyl groups to DNA bases, resulting in the DNA being fragmented by repair enzymes in their attempts to replace the alkylated bases, preventing DNA synthesis and RNA transcription from the affected DNA, 2) DNA damage via the formation of cross-links (bonds between atoms in the DNA) which prevents DNA from being separated for synthesis or transcription, and 3) the induction of mispairing of the nucleotides leading to mutations.

    As an alkylating agent, chlorambucil interferes with DNA replication and transcription of RNA, and ultimately results in the disruption of nucleic acid function. In vitro studies have shown that the major metabolite of chlorambucil (phenylacetic acid mustard), which is also a bifunctional alkylating compound, has antineoplastic activity against some neoplastic human cell lines that is approximately equal to that of chlorambucil. Therefore, the major metabolite of chlorambucil may contribute to the in vivo antitumor activity of the drug. Chlorambucil also possesses some immunosuppressive activity, principally due to its suppression of lymphocytes. The drug is the slowest acting and generally least toxic of the presently available nitrogen mustard derivatives.

    American Society of Health-System Pharmacists 2011; Drug Information 2011. Bethesda, MD. 2011, p. 983

    A marked transient increase was observed in ribonucleotide reductase activity within 2 hr of exposing BALB/c 3T3 mouse cells to DNA damaging concentrations of chlorambucil. Elevations in activity were accompanied by transient increases in the mRNA levels of both genes (R1 and R2) that code for ribonucleotide reductase. Only the protein for the limiting component for enzyme activity R2 was significantly elevated in chlorambucil treated cultures. The chlorambucil effects upon activity and regulation of ribonucleotide reductase occurred without any detectable changes in the rate of DNA synthesis, as would be expected if the elevation in enzyme activity is required for DNA repair. The chlorambucil-induced elevations in R1 and R2 message levels were blocked by treatment of cells with actinomycin D or the tumor promoter 12-O-tetradecanoylphorbol-13-acetate indicating the importance of the reductase transcriptional process in responding to the action of chlorambucil and providing evidence for the involvement of a protein kinase C pathway in the regulation of mammalian ribonucleotide reductase. In addition to the chlorambucil-induced elevations in enzyme activity, message, and protein levels, the drug was also shown to be an inhibitor of ribonucleotide reductase activity in cell-free preparations. Both R1 and R2 proteins were targets for chlorambucil, in keeping with the known alkylating abilities of the drug.

    PMID:1551913 Hurta RA, Wright JA; J Biol Chem 267 (10): 7066-71 (1992)

    /ALTERNATIVE and IN VITRO TESTS/ Reaction of one of the two chloroethyl groups of chlorambucil with the N7 position of guanine or adenine of double-stranded DNA leads to the formation of mono-adducts. These are repaired rapidly in an error-free fashion by methylguanine methyltransferase (sometimes called alkylguanine alkyltransferase). However, some cells lack this repair activity, usually because of silencing of the corresponding gene, and the unrepaired DNA mono-adduct then forms a complex with mismatch-repair enzymes. The subsequent inhibition of DNA replication can eventually induce DNA breakage. The second chloroethyl group of the DNA mono-adduct with chlorambucil can interact with proteins but more importantly, because of its juxtaposition to other bases in the major groove of DNA, it can react with a DNA base to form an interstrand DNA cross-link. This DNA crosslink complex is quite stable, and its repair requires nucleotide excision repair factors (such as xeroderma pigmentosum complementation group F-excison repair cross-complementing rodent repair deficiency, complementation group, 1-XPF-ERCC1) that act slowly by homologous recombination. The DNA cross-link attracts several binding proteins, probably the BRCA1 and BRCA2 proteins, Fanconi anemia gene product, and Nijmegen breakage syndrome gene product to form a complex. As shown in cultured HeLa cells, addition of chlorambucil prolongs S-phase and induces a corresponding mitotic delay. The magnitude of these effects correlates with the level of DNA cross-links. Treatment of cells in the G2-phase of the cell cycle does not induce mitotic delay but does inhibit DNA synthesis in the subsequent cell cycle, and causes a delay in the next mitosis, suggesting that at least some lesions induced by chlorambucil are long-lasting.

    IARC. Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Geneva: World Health Organization, International Agency for Research on Cancer, 1972-PRESENT. (Multivolume work). Available at: https://monographs.iarc.fr/ENG/Classification/index.php, p. V100A 52 (2012)

    API SUPPLIERS

    read-more
    read-more
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    API Reference Price

    read-more
    read-more
    [{"dataSource":"API Import","activeIngredients":"","year":"2021","qtr":"Q3","strtotime":1632853800,"product":"CHLORAMBUCIL (QTY:2X1 GMS, PRICE:USD149.74\/EACH)(FOC)","address":"106, FIRST FLOOR , ASHOKA BHOOPALCHAMBERS BEGUMPET, S.P. ROAD,","city":"HYDERABAD-A.P.","supplier":"THE U.S. PHARMACOPEIAL ","supplierCountry":"UNITED STATES","foreign_port":"","customer":"UNITED STATES PHARMACOPEIA - INDIA PRIVATE LIMITED","customerCountry":"INDIA","quantity":"0.00","actualQuantity":"0.001","unit":"KGS","unitRateFc":"299480","totalValueFC":"312.2","currency":"USD","unitRateINR":"22964430","date":"29-Sep-2021","totalValueINR":"22964.43","totalValueInUsd":"312.2","indian_port":"HYDERABAD AIR","hs_no":"29224990","bill_no":"5625795","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"","supplierAddress":"","customerAddress":"106, FIRST FLOOR , ASHOKA BHOOPALCHAMBERS BEGUMPET, S.P. ROAD,"},{"dataSource":"API Import","activeIngredients":"","year":"2021","qtr":"Q3","strtotime":1632853800,"product":"CHLORAMBUCIL (QTY:4X125 MGS, PRICE: USD 200\/EACH) (FOC)","address":"106, FIRST FLOOR , ASHOKA BHOOPALCHAMBERS BEGUMPET, S.P. ROAD,","city":"HYDERABAD-A.P.","supplier":"THE U.S. PHARMACOPEIAL ","supplierCountry":"UNITED STATES","foreign_port":"","customer":"UNITED STATES PHARMACOPEIA - INDIA PRIVATE LIMITED","customerCountry":"INDIA","quantity":"0.00","actualQuantity":"0.0005","unit":"KGS","unitRateFc":"1600000","totalValueFC":"834","currency":"USD","unitRateINR":"122689640","date":"29-Sep-2021","totalValueINR":"61344.82","totalValueInUsd":"834","indian_port":"HYDERABAD AIR","hs_no":"29224990","bill_no":"5625795","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"","supplierAddress":"","customerAddress":"106, FIRST FLOOR , ASHOKA BHOOPALCHAMBERS BEGUMPET, S.P. ROAD,"},{"dataSource":"API Import","activeIngredients":"","year":"2023","qtr":"Q2","strtotime":1685903400,"product":"CHLORAMBUCIL USP","address":"SY.NO. 342, PLOT NOS. 118,119 & 120 ALEAP INDL. ESTATE, ROAD NO. 6","city":"PRAGATHI NAGAR, HYDERABAD,TELANGANA","supplier":"HANWEISHI PHARMCHEM","supplierCountry":"CHINA","foreign_port":"NA","customer":"THERDOSE PHARMA","customerCountry":"INDIA","quantity":"0.03","actualQuantity":"25","unit":"GMS","unitRateFc":"22","totalValueFC":"558.1","currency":"USD","unitRateINR":"1835.1","date":"05-Jun-2023","totalValueINR":"45869.978","totalValueInUsd":"558.1","indian_port":"HYDERABAD AIR","hs_no":"29299090","bill_no":"0","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"SY.NO. 342, PLOT NOS. 118,119 & 120 ALEAP INDL. ESTATE, ROAD NO. 6"}]
    29-Sep-2021
    05-Jun-2023
    KGS
    overview
    Loading...

    Average Price (USD/KGS)

    Number of Transactions

    Total Quantity (KGS)

    Total Value (USD)

    Quantity (KGS) & Unit rate (USD/KGS) over time

    API Imports and Exports

    Importing Country Total Quantity
    (KGS)    		 Average Price
    (USD/KGS)    		 Number of Transactions

    Upgrade, download data, analyse, strategize, subscribe with us contact

    Related Excipient Companies

    Upload your portfolio for free, ask us

    Excipients by Applications

    Click here to find the perfect excipient manufacturers by their capabilities

    Coating Systems & Additives

    read-more
    read-more

    Fillers, Diluents & Binders

    read-more
    read-more

    Controlled & Modified Release

    read-more
    read-more

    Direct Compression

    read-more
    read-more

    Thickeners and Stabilizers

    read-more
    read-more

    Granulation

    read-more
    read-more

    Film Formers & Plasticizers

    read-more
    read-more

    Co-Processed Excipients

    read-more
    read-more

    Topical

    read-more
    read-more

    Lubricants & Glidants

    read-more
    read-more

    Disintegrants & Superdisintegrants

    read-more
    read-more

    Empty Capsules

    read-more
    read-more

    Solubilizers

    read-more
    read-more

    Vegetarian Capsules

    read-more
    read-more

    API Stability Enhancers

    read-more
    read-more

    Taste Masking

    read-more
    read-more

    Coloring Agents

    read-more
    read-more

    Emulsifying Agents

    read-more
    read-more

    Chewable & Orodispersible Aids

    read-more
    read-more

    Rheology Modifiers

    read-more
    read-more

    Parenteral

    read-more
    read-more

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    DATA COMPILATION #PharmaFlow

    read-more
    read-more

    NEWS #PharmaBuzz

    read-more
    read-more

    Global Sales Information

    Do you need Business Intel? Ask us

    Market Place

    Do you need sourcing support? Ask us

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    USP

    read-more
    read-more

    ANALYTICAL

    Upload your methods for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search